RS PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
RS PHARMA
Largest movements
- Cash +€67,143
up €67,143 (+68.9%), from €97,507 to €164,650
mainly Other debts (+€156,000) and Net result for the year (+€76,398)
- Tangible fixed assets +€5,522
up €5,522 (+122.2%), from €4,521 to €10,043
- Deferred charges and accrued income -€2,230
down €2,230 (-90.3%), from €2,471 to €241
- Other debts +€156,000
up €156,000 (+3588.9%), from €4,347 to €160,347
- Profit (loss) carried forward -€83,602
down €83,602 (-78.2%), from €106,842 to €23,240
- Gross operating margin +€15,736
up €15,736 (+14.8%), from €106,091 to €121,827
- Staff costs +€5,220
up €5,220 (+57.4%), from €9,100 to €14,320
- Depreciation +€1,740
up €1,740 (+140.9%), from €1,235 to €2,975
- Taxes +€1,398
up €1,398 (+5.6%), from €25,123 to €26,521
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €129,675 | €201,141 | +€71,466 | +55.1% |
| Fixed assets | 21/28 | €4,521 | €10,043 | +€5,522 | +122.2% |
| Tangible fixed assets | 22/27 | €4,521 | €10,043 | +€5,522 | +122.2% |
| Furniture and vehicles | 24 | €4,521 | €10,043 | +€5,522 | +122.2% |
| Current assets | 29/58 | €125,154 | €191,098 | +€65,944 | +52.7% |
| Amounts receivable within one year | 40/41 | €25,176 | €26,207 | +€1,031 | +4.1% |
| Trade receivables | 40 | €25,176 | €26,207 | +€1,031 | +4.1% |
| Cash at bank and in hand | 54/58 | €97,507 | €164,650 | +€67,143 | +68.9% |
| Deferred charges and accrued income | 490/1 | €2,471 | €241 | -€2,230 | -90.3% |
| Total equity and liabilities | 10/49 | €129,675 | €201,141 | +€71,466 | +55.1% |
| Equity | 10/15 | €111,842 | €28,240 | -€83,602 | -74.8% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €106,842 | €23,240 | -€83,602 | -78.2% |
| Amounts payable | 17/49 | €17,833 | €172,901 | +€155,068 | +869.5% |
| Amounts payable within one year | 42/48 | €17,833 | €172,901 | +€155,068 | +869.5% |
| Trade debts | 44 | €2,387 | €1,344 | -€1,043 | -43.7% |
| Suppliers | 440/4 | €2,387 | €1,344 | -€1,043 | -43.7% |
| Taxes, remuneration and social security | 45 | €11,100 | €11,211 | +€111 | +1.0% |
| Taxes | 450/3 | €9,798 | €10,921 | +€1,123 | +11.5% |
| Remuneration and social security | 454/9 | €1,302 | €290 | -€1,012 | -77.7% |
| Other amounts payable | 47/48 | €4,347 | €160,347 | +€156,000 | +3588.9% |
| Remuneration, social security and pensions | 62 | €9,100 | €14,320 | +€5,220 | +57.4% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,235 | €2,975 | +€1,740 | +140.9% |
| Other operating charges | 640/8 | €1,384 | €1,462 | +€78 | +5.6% |
| Gross operating margin | 9900 | €106,091 | €121,827 | +€15,736 | +14.8% |
| Operating profit (loss) | 9901 | €94,371 | €103,070 | +€8,698 | +9.2% |
| Financial income | 75/76B | - | €2 | +€2 | |
| Recurring financial income | 75 | - | €2 | +€2 | |
| Financial charges | 65/66B | €102 | €153 | +€51 | +50.0% |
| Recurring financial charges | 65 | €102 | €153 | +€51 | +50.0% |
| Profit (loss) for the period before taxes | 9903 | €94,269 | €102,918 | +€8,649 | +9.2% |
| Income taxes | 67/77 | €25,123 | €26,521 | +€1,398 | +5.6% |
| Profit (loss) for the period | 9904 | €69,146 | €76,398 | +€7,251 | +10.5% |
| Profit (loss) for the period to be appropriated | 9905 | €69,146 | €76,398 | +€7,251 | +10.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.